Ralf Schmid, formerly Chief Financial Officer (CFO), has taken over from Dr. David Chiswell as Chief Executive Officer (CEO). Dr. Chiswell reverts to his previous role as non-executive chairman of Nabriva’s supervisory board replacing Dr. Denise Pollard-Knight who will remain on the board as Deputy Chair.
In addition to Ralf Schmid (CEO) and William Prince Chief Medical Officer (CMO) there are two new members of management board: Dr. Werner Heilmayer, who has been promoted from Head to Vice President of Chemistry, Manufacturing and Controls & Intellectual Property (VP CMC & IP) and Dr. Zrinka Ivezic-Schönfeld promoted to Vice President Non-Clinical (VP Non-Clinical) from Head of Clinical Sciences.
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by S. aureus, S. pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, L. pneumophila and other bacteria, including drug resistant strains such as MRSA and Vancomycin resistant Enterococcus faecium. Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva’s current shareholders include: Phase4 Ventures, HBM Partners, Wellcome Trust Investments 3 Unlimited, Global Life Science Ventures, Novartis Venture Fund and Sandoz. Nabriva Therapeutics is located in Vienna, Austria.
For more information on Nabriva please visit www.nabriva.com